X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (88) 88
humans (76) 76
index medicus (71) 71
cancer (46) 46
female (40) 40
immunotherapy (35) 35
male (34) 34
middle aged (34) 34
animals (29) 29
aged (27) 27
care and treatment (23) 23
chemotherapy (23) 23
adult (22) 22
mice (22) 22
tumors (22) 22
dendritic cells (21) 21
therapy (20) 20
aged, 80 and over (18) 18
antineoplastic agents - therapeutic use (16) 16
immunology (16) 16
treatment outcome (16) 16
survival (15) 15
antibodies, monoclonal - therapeutic use (14) 14
cell line, tumor (14) 14
research (14) 14
analysis (13) 13
biomarkers (13) 13
monoclonal antibodies (13) 13
health aspects (12) 12
lung cancer (12) 12
medicine & public health (12) 12
metastasis (12) 12
clinical trials (11) 11
expression (11) 11
patients (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
carcinoma (10) 10
melanoma (10) 10
neoplasms - immunology (10) 10
neoplasms - therapy (10) 10
t cells (10) 10
t-lymphocytes - immunology (10) 10
dendritic cells - immunology (9) 9
in-vivo (9) 9
monoclonal-antibodies (9) 9
nivolumab (9) 9
oncology, experimental (9) 9
prognosis (9) 9
sunitinib (9) 9
tumor necrosis factor receptor superfamily, member 9 - immunology (9) 9
cancer therapies (8) 8
disease-free survival (8) 8
immunity (8) 8
lung neoplasms - drug therapy (8) 8
mice, inbred c57bl (8) 8
mutation (8) 8
resistance (8) 8
antitumor immunity (7) 7
apoptosis (7) 7
cd137 (7) 7
cd8 t-cells (7) 7
cisplatin (7) 7
cytokines (7) 7
diagnosis (7) 7
double-blind (7) 7
established tumors (7) 7
follow-up studies (7) 7
genetic aspects (7) 7
medical prognosis (7) 7
pathology (7) 7
prostate cancer (7) 7
regulatory t-cells (7) 7
research article (7) 7
risk factors (7) 7
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
biotechnology & applied microbiology (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
carcinoma, renal cell - drug therapy (6) 6
cell lung-cancer (6) 6
cells (6) 6
disease progression (6) 6
gemcitabine (6) 6
gene expression (6) 6
gene therapy (6) 6
immunotherapy - methods (6) 6
interferon-alpha (6) 6
ipilimumab (6) 6
kidney neoplasms - drug therapy (6) 6
kidney neoplasms - pathology (6) 6
lymphocytes (6) 6
lymphocytes t (6) 6
medicine (6) 6
medicine, research & experimental (6) 6
mitoxantrone (6) 6
neoplasm staging (6) 6
neoplasms - drug therapy (6) 6
proteins (6) 6
sorafenib (6) 6
t-cells (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CHEMISTRY, ISSN 0009-9147, 01/2015, Volume 61, Issue 1, pp. 297 - 304
BACKGROUND: Around 50% of cutaneous melanomas harbor the BRAF(V600E) mutation and can be treated with BRAF inhibitors. DNA carrying this mutation can be... 
BIOMARKERS | PLASMA | ASSAY | DNA | RELEVANCE | RESISTANCE | MARKERS | KRAS | MEDICAL LABORATORY TECHNOLOGY | CANCER | TUMORS
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2011, Volume 22, Issue 12, pp. 2646 - 2653
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 08/2015, Volume 42, Issue 4, pp. 640 - 655
T and natural killer (NK) lymphocytes are considered the main effector players in the immune response against tumors. Full activation of T and NK lymphocytes... 
IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES | GROWTH-FACTOR RECEPTOR | TUMOR-NECROSIS-FACTOR | ONCOLOGY | IN-VIVO | REGULATORY T-CELLS | SINGLE-CHAIN FV | ANTITUMOR IMMUNITY | TARGETING 4-1BB COSTIMULATION | IMMUNOLOGICAL SYNAPSE | VIRAL-INFECTION
Journal Article
Cancer Research, ISSN 0008-5472, 10/2016, Volume 76, Issue 20, pp. 5994 - 6005
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2013, Volume 19, Issue 5, pp. 997 - 1008
Immune system responses are under the control of extracellular biomolecules, which express functions in receptors present on the surface of cells of the immune... 
DACETUZUMAB SGN-40 | ONCOLOGY | PROGRAMMED DEATH-1 | IMMUNE-RESPONSES | DENDRITIC CELL | B7 FAMILY | REGULATORY T | CD40 LIGATION | PHASE-I | CANCER | CD8(+) T-CELLS | T-Lymphocytes, Cytotoxic - immunology | Cancer Vaccines - therapeutic use | Immunization | Neoplasms - therapy | Animals | Neoplasms - immunology | Humans | Drug Design | Antibodies, Monoclonal - therapeutic use
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6115 - 6124
Immune checkpoint inhibitors (ICI) have emerged as a novel therapeutic strategy that achieves significant clinical benefit in several tumor types, including... 
ANTIBODY-DRUG CONJUGATE | SUPPORTIVE CARE | MULTICENTER | VINFLUNINE PLUS | THERAPY | ONCOLOGY | COMPREHENSIVE MOLECULAR CHARACTERIZATION | CISPLATIN-INELIGIBLE PATIENTS | OPEN-LABEL | SINGLE-ARM | CARCINOMA
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 1, pp. 81 - 88
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2016, Volume 22, Issue 22, pp. 5461 - 5471
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 09/2015, Volume 75, Issue 17, pp. 3466 - 3478
A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here, we... 
IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES | SURVIVAL | CELLS | RESPONSES | ANTI-PD-L1 ANTIBODY | ONCOLOGY | SAFETY | MOUSE | HOST-DISEASE | BLOCKADE | IPILIMUMAB
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article